From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity ...

Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

A year of recovery After a challenging period, 2024 has seen a more positive backdrop emerge for the biotechnology sector. In ...

BMS has now acquired all outstanding stock in the $330-per-share transaction, gaining full control of KarXT (xanomeline tartrate/trospium chloride), a drug that could become the first to reach the ...

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...

In a report released on September 27, Faisal Khurshid from Leerink Partners reiterated a Buy rating on PureTech Health (PRTC – Research ...

Israeli troops crossed the border for the first time since 2006 in a ground operation targeting Hezbollah. The Israeli military called for evacuations in southern Lebanon. As a Crisis Builds ...

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...